The U.S. FDA has approved a single tablet combination of macitentan and tadalafil for the treatment of pulmonary artery hypertension. This medication offers a convenient option for patients with this condition. The combination of macitentan and tadalafil has been shown to be effective in improving symptoms and quality of life for individuals with pulmonary artery hypertension. This approval provides patients with a new treatment option for managing their condition. The use of cookies on our site is for analytics, advertising, and site improvement, and by continuing to use our site, you agree to our cookie policy.
Source link
Single tablet combo of macitentan and tadalafil receives US FDA approval for pulmonary artery hypertension
